slc44a4 Antibody

What is SLC44A4 and why is it important in research?

SLC44A4 (solute carrier family 44 member 4) is a member of a family of putative choline transporters that has gained significance in cancer research due to its marked upregulation in various epithelial tumors, particularly prostate and pancreatic cancers . The protein is approximately 79.3 kilodaltons in mass and may also be identified as CTL4, C6orf29, DFNA72, NG22, choline transporter-like protein 4, or testicular tissue protein Li 48 . Its importance as a novel target in epithelial-origin cancers has driven the development of specific antibodies for detection and therapeutic applications, including antibody-drug conjugates such as ASG-5ME .

What are the common applications for SLC44A4 antibodies in research?

SLC44A4 antibodies are employed in multiple research applications, with the most common being immunohistochemistry (IHC), Western blotting (WB), ELISA, flow cytometry (FCM), and immunofluorescence (IF) . These applications allow researchers to detect and quantify SLC44A4 expression in various experimental systems including cell lines, xenografts, and patient-derived samples. For immunohistochemical studies, antibodies such as the monoclonal antibody M5-121.131 targeting an extracellular domain of human SLC44A4 have been validated for specificity through correlation of staining patterns on formalin-fixed, paraffin-embedded sections with transcript expression data .

What types of SLC44A4 antibodies are available for research purposes?

Research-grade SLC44A4 antibodies come in various forms with distinct characteristics:

• Host species: Mouse monoclonal and other species-derived antibodies are available

• Reactivity profiles: Antibodies with specificity for human SLC44A4, as well as cross-reactive antibodies that recognize orthologs in experimental animal models (mouse, rat, rabbit, etc.)

• Conjugation status: Both unconjugated antibodies and those conjugated to detection molecules for specific applications

• Target epitopes: Antibodies targeting different domains of the SLC44A4 protein, such as the middle region or extracellular domains

Selection of the appropriate antibody depends on the specific research application, model system, and experimental design.

How can researchers validate the specificity of SLC44A4 antibodies?

Validation of SLC44A4 antibody specificity requires multiple complementary approaches. The following methodology is recommended based on established protocols:

• Correlation analysis: Compare antibody staining patterns on formalin-fixed, paraffin-embedded (FFPE) sections of various xenografts and cell lines with available transcript expression data

• FACS analysis: Confirm specificity using recombinant cell lines expressing SLC44A4 compared to control cell lines not expressing the target

• Western blot validation: Assess detection of the appropriate molecular weight band (79.3 kDa) in SLC44A4-expressing samples versus controls

• Immunoprecipitation followed by mass spectrometry: To confirm the identity of the antibody-bound protein

• Use of genetic knockdown or knockout models: Evaluate loss of signal in systems where SLC44A4 expression has been eliminated

These validation steps are critical to ensure experimental reproducibility and accurate interpretation of results in SLC44A4 research.

What are the optimal conditions for immunohistochemical detection of SLC44A4?

For optimal immunohistochemical detection of SLC44A4 in tissue samples, researchers should consider the following methodological approach:

• Sample preparation: Use formalin-fixed, paraffin-embedded (FFPE) sections with appropriate antigen retrieval techniques

• Primary antibody selection: Utilize validated SLC44A4-specific antibodies (e.g., M5-121.131) targeting extracellular domains

• Control samples: Include isotype control antibody (e.g., mouse IgG1k) for comparison

• Detection system: Apply sensitive detection methods such as polymer-HRP IHC detection systems

• Scoring system: Implement a comprehensive scoring system based on both staining intensity and percentage of positively staining cells

A recommended scoring approach includes evaluating average staining intensity on a scale of 0-4 (none to strong) and percentage of positive cells on a scale of 0-4 (none to >75%), with categorization into high/moderate (≥50% of tumor cells with intensity score of 2-4), low, or negative expressions .

How can researchers generate recombinant SLC44A4 protein for experimental use?

Generation of recombinant SLC44A4 protein domains, particularly for antibody production or binding studies, can be accomplished using the following procedure:

• Select the domain of interest: For example, the first extracellular domain (amino acids 50-227) has been successfully generated

• Choose an appropriate expression vector: Modified versions of expression vectors such as pAPTag5 have been employed successfully

• Express in mammalian or bacterial expression systems: Selection depends on requirements for post-translational modifications

• Purify using affinity tags: Incorporate appropriate affinity tags to facilitate purification

• Validate structural integrity: Confirm proper folding and functionality through binding assays with known interaction partners

This recombinant protein can serve as a valuable tool for antibody screening, specificity testing, and mechanistic studies of SLC44A4 function.

How can researchers establish SLC44A4-expressing cell line models?

To generate stable cell line models expressing SLC44A4 for research purposes, the following methodology has been successfully employed:

• Select appropriate parental cell lines: Both human (PC3) and rodent (3T3 clone 7, Rat1, 300.19) cell lines have been used successfully as hosts

• Utilize retroviral transduction: Apply replication-deficient retroviral vector systems such as pSRalpha-MSV-TKneo amphotropic retroviral vectors encoding SLC44A4

• Select for stable expression: Use antibiotic selection (e.g., G418) to isolate cells with stable integration

• Generate control cell lines: Create matched control cells using the same vector expressing only the antibiotic resistance gene

• Validate expression: Confirm stable SLC44A4 expression through FACS analysis and Western blotting

These cell models provide valuable tools for studying SLC44A4 function, antibody binding properties, and potential therapeutic approaches targeting this protein.

What approaches are used to measure antibody and antibody-drug conjugate (ADC) affinity for SLC44A4?

Determination of antibody and ADC affinity for SLC44A4 requires rigorous binding analysis using the following methodological approach:

• Cell preparation: Utilize recombinant cells expressing either human or cynomolgus SLC44A4, with negative control cells expressing only the selection marker

• Serial dilution analysis: Prepare antibodies or ADCs in a dilution curve (e.g., 0.01 to 160 nmol/L)

• Flow cytometry-based binding assay: Incubate cells with antibodies or ADCs at 4°C overnight, followed by washing and addition of appropriate detection antibodies

• Data analysis: Apply one-site binding, nonlinear regression analysis to determine KD (equilibrium dissociation constant) and Bmax (maximum specific binding) values

• Control inclusion: Always include isotype control antibodies and corresponding ADCs as negative controls

This approach enables accurate quantification of binding parameters critical for both research applications and therapeutic development.

How can internalization of SLC44A4-targeted antibodies be assessed?

Evaluation of antibody internalization is crucial for understanding the potential of SLC44A4 as a therapeutic target, particularly for antibody-drug conjugates. The following confocal microscopy-based methodology is recommended:

• Cell preparation: Seed recombinant cells expressing SLC44A4 onto appropriate substrates (e.g., poly-D-lysine coated chamber slides)

• Antibody labeling: Label antibodies with appropriate fluorescent markers that allow tracking over time

• Time-course imaging: Perform confocal microscopy at various time points to track antibody localization

• Co-localization studies: Use markers for cellular compartments (endosomes, lysosomes) to confirm internalization pathway

• Quantitative analysis: Apply image analysis software to quantify internalization rates and efficiency

This methodology provides insights into the cellular fate of SLC44A4-targeted antibodies, which is essential information for developing effective targeted therapies.

What is the expression pattern of SLC44A4 in various cancer types?

SLC44A4 shows distinct expression patterns across cancer types, with particularly notable upregulation in epithelial tumors. Based on available research data:

Expression analysis typically employs a scoring system combining staining intensity (0-4) and percentage of positive cells (0-4) . High/moderate expression is defined as ≥50% of tumor cells with an average intensity score of 2-4, while other positive samples are classified as low expression .

How can researchers evaluate the therapeutic potential of SLC44A4-targeted antibody-drug conjugates?

Evaluation of SLC44A4-targeted ADCs requires comprehensive in vivo activity studies following this methodological approach:

• Model selection: Utilize either cell line-derived xenograft models or patient-derived tumor xenografts (PDX) established in immunodeficient mice (e.g., ICR-SCID)

• Implantation method: Establish tumors either subcutaneously or orthotopically through injection of human tumor cells or fragments of PDXs

• Target validation: Confirm SLC44A4 expression in all xenograft models through IHC analysis

• Treatment protocol: Administer test compounds according to predetermined dosing schedules

• Monitoring: Track tumor growth using caliper measurements every 3-4 days, calculating tumor volume as width² × length/2

• Data analysis: Perform statistical analysis of tumor volume data using appropriate tests (e.g., Kruskal-Wallis followed by Tukey test procedures)

• Efficacy calculation: Determine percent tumor growth inhibition in treated versus control groups

This approach provides robust data on the potential therapeutic efficacy of SLC44A4-targeted interventions in relevant cancer models.

What are the considerations for developing SLC44A4-specific human monoclonal antibodies?

Development of SLC44A4-specific human monoclonal antibodies for research or therapeutic applications involves several specialized methodological considerations:

• Immunization strategy: For humanized antibodies, immunize transgenic mice (e.g., Xenomice producing human IgG2) with cells engineered to express SLC44A4

• Hybridoma generation: Fuse lymph node cells from immunized mice with appropriate myeloma cells (e.g., Sp2/0-AG14) using techniques such as electro cell fusion

• Screening approach: Identify SLC44A4-specific hybridomas by screening for binding to cells engineered to express specific domains of SLC44A4 (e.g., loop one of the multi-transmembrane protein)

• Conjugation strategy: For ADC development, consider appropriate linker chemistry (e.g., protease-cleavable valine-citrulline linker) and payloads (e.g., monomethyl auristatin E)

• Characterization: Thoroughly evaluate binding specificity, affinity, internalization properties, and functional effects

This systematic approach has been successfully employed to develop therapeutic candidates such as ASG-5ME, an antibody-drug conjugate targeting SLC44A4-positive epithelial tumors .

What are common challenges in SLC44A4 antibody-based research and how can they be addressed?

Researchers frequently encounter several challenges when working with SLC44A4 antibodies. Here are methodological approaches to address them:

• Specificity concerns:

  • Validate antibodies using multiple techniques including Western blot, IHC, and flow cytometry

  • Compare results across multiple antibody clones targeting different epitopes

  • Use SLC44A4 knockout or knockdown models as negative controls

• Signal detection issues:

  • Optimize antigen retrieval methods for IHC applications

  • Test multiple detection systems to enhance sensitivity

  • Consider signal amplification methods for low-abundance expression

• Cross-reactivity with other SLC family members:

  • Select antibodies specifically validated against other SLC family proteins

  • Perform competitive binding assays with recombinant SLC proteins

  • Verify results using orthogonal detection methods

• Variability in SLC44A4 expression across models:

  • Carefully characterize expression levels before experimental design

  • Consider inducible expression systems for controlled studies

  • Account for microenvironmental factors that may influence expression

These targeted approaches can significantly improve experimental outcomes in SLC44A4 research.

How can researchers optimize immunohistochemical scoring systems for SLC44A4 expression?

Developing robust scoring systems for SLC44A4 expression in tissue samples requires methodological rigor:

• Establish a multi-dimensional scoring system incorporating:

  • Staining intensity on a 0-4 scale (none, weak, mild, moderate, strong)

  • Percentage of positively stained tumor cells in categories (0% = 0, >0-25% = 1, >25-50% = 2, >50-75% = 3, >75% = 4)

• Implement categorical classification:

  • High/moderate: ≥50% of tumor cells with average intensity of 2-4

  • Low: Other positive samples

  • Negative: No staining

• Ensure scoring consistency through:

  • Training of multiple observers

  • Blinded scoring by independent pathologists

  • Use of digital image analysis when possible

  • Reference standards for each intensity category

• Validation steps:

  • Correlate IHC scores with mRNA expression data when available

  • Assess reproducibility across multiple tissue sections

  • Compare results across different antibody clones

This comprehensive approach reduces subjectivity and improves reproducibility in SLC44A4 expression analysis.

What are emerging applications of SLC44A4 antibodies beyond cancer research?

While current research focuses primarily on SLC44A4's role in cancer, its identity as a putative choline transporter suggests broader applications:

• Neurological research: Given the importance of choline transport in neurotransmitter synthesis, SLC44A4 antibodies may prove valuable in studying:

  • Cholinergic neuron function

  • Neurological disorders involving cholinergic pathways

  • Brain region-specific expression patterns

• Metabolic studies: As choline is crucial for phospholipid synthesis, SLC44A4 antibodies could illuminate:

  • Membrane biogenesis mechanisms

  • Metabolic adaptations in various physiological states

  • Lipid metabolism disorders

• Developmental biology: Tracking SLC44A4 expression during development could reveal:

  • Tissue-specific differentiation processes

  • Critical periods of choline requirement

  • Developmental disorders linked to choline transport

• Immunological applications: Exploring SLC44A4's potential role in immune cell function through:

  • Expression profiling across immune cell populations

  • Functional studies during immune activation

  • Relationship to inflammatory conditions

These emerging applications will require rigorous validation of antibody specificity in these novel contexts.

How might advanced imaging techniques enhance SLC44A4 antibody applications in research?

Integration of cutting-edge imaging methodologies with SLC44A4 antibodies presents significant research opportunities:

• Super-resolution microscopy:

  • Nanoscale localization of SLC44A4 within membrane microdomains

  • Co-localization with interaction partners at previously unresolvable resolution

  • Tracking of single-molecule dynamics in living cells

• Intravital microscopy:

  • Real-time visualization of SLC44A4-targeted antibodies in tumor microenvironments

  • Assessment of ADC penetration and distribution in vivo

  • Monitoring of dynamic responses to therapeutic interventions

• Correlative light and electron microscopy (CLEM):

  • Ultrastructural context of SLC44A4 localization

  • Precise membrane topology at nanometer resolution

  • Visualization of internalization pathways

• Multiplexed imaging:

  • Simultaneous detection of SLC44A4 with multiple markers

  • Spatial relationship to the tumor microenvironment

  • Complex phenotyping of heterogeneous samples

These advanced approaches will provide unprecedented insights into SLC44A4 biology and therapeutic targeting potential.